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Objectives: Proton pump inhibitors (PPIs) can limit the solubility of concomitant drugs, which can lead to
decreased absorption and exposure. Reduced efficacy can be a consequence and in the case of an antimicrobial
agent this may contribute to development of resistance. Patients chronically infected with the hepatitis C virus
can be treated with a boceprevir-containing regimen and it is relevant to know if interactions between PPIs and
boceprevir exist. This study was designed to investigate the influence of a frequently used PPI, omeprazole, on
the pharmacokinetics of boceprevir and vice versa.
Methods: In this open-label, three-period, randomized, cross-over, Phase I study, healthy subjects were ran-
domly assigned to 40 mg of omeprazole once daily for 5 days, 800 mg of boceprevir three times daily for
5 days and 40 mg of omeprazole once daily+800 mg of boceprevir three times daily for 5 days, or the
same treatment in a different order. Every treatment was followed by a wash-out period. At day 5 of every
treatment pharmacokinetic blood sampling was performed for 8 h after medication intake. ClinicalTrials.gov:
NCT01470690.
Results: All 24 subjects (15 males) completed the study and no serious adverse events were reported. Geomet-
ric mean ratios (90% CI) of the area under the plasma concentration–time curve up to 8 h (AUC0–8) and
maximum plasma concentration (Cmax) of boceprevir with omeprazole versus boceprevir alone were 0.92
(0.87–0.97) and 0.94 (0.86–1.02), respectively. For omeprazole these values were 1.06 (0.90–1.25) for
AUC0–8 and 1.03 (0.85–1.26) for Cmax for the combination versus omeprazole alone.
Conclusions: Omeprazole did not have a clinically significant effect on boceprevir exposure, and boceprevir did
not affect omeprazole exposure.
Keywords: drug interactions, pharmacokinetics, hepatitis C virus, PPIs
Introduction
Proton pump inhibitors (PPIs) are among the most commonly
used drugs worldwide, as they are (self-)prescribed for several
acid-related disorders. It is well known that they can affect the
bioavailability of other drugs.1 By their ability to increase the
pH in the stomach, PPIs can limit the solubility of other drugs
and hence lead to decreased absorption and lower plasma con-
centrations.1 For example, PPIs decrease the absorption of some
oral tyrosine kinase inhibitors (e.g. dasatinib and erlotinib),2,3
various antifungal agents (e.g. ketoconazole, itraconazole and
posaconazole),4–7 mycophenolate mofetil8,9 and a number of
drugs used to treat HIV (e.g. rilpivirine, atazanavir, nelfinavir
and indinavir).10–15
Boceprevir is an NS3 serine protease inhibitor that is approved
for the treatment of chronic hepatitis C virus (HCV) genotype 1
infection, in combination with pegylated interferon alfa and riba-
virin.16 Since PPIs are widely prescribed it is very likely that
HCV-infected patients will use boceprevir and a PPI simultan-
eously. The effect of gastric pH elevation by a PPI on boceprevir
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solubility and absorption is currently unknown. It is, however,
relevant to know whether there is a drug–drug interaction that
can significantly influence the bioavailability of boceprevir, in
order to prevent inadequate exposure to boceprevir, which
might lead to reduced efficacy or even resistance to this protease
inhibitor. At the moment a pharmacokinetic drug–drug inter-
action study is lacking.
This pharmacokinetic study in healthy volunteers was per-
formed in order to assess the effect of steady-state omeprazole,
the prototype PPI, on the pharmacokinetics of boceprevir and
vice versa, and to evaluate the safety and tolerability of the
combination.
Methods
Study design
This open-label, three-period, randomized, cross-over, Phase I study was
conducted from October to December 2011 at the Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands. The study was
designed to determine the effect of multiple-dose omeprazole on the
pharmacokinetics of boceprevir by intra-subject comparison. The second-
ary objective was to examine the effect of steady-state boceprevir on the
pharmacokinetics of omeprazole, again by intra-subject comparison, and
to study the safety of steady-state boceprevir combined with multiple-
dose omeprazole.
Healthy volunteers were equally randomized to one of the following
regimen sequences: ABC; ACB; BCA; BAC; CAB; or CBA. The regimens
were: regimen A, 40 mg of omeprazole once daily for 5 consecutive
days (omeprazole alone); regimen B, 800 mg of boceprevir three times
daily (8 h intervals) for 4 consecutive days+a single dose of 800 mg on
day 5 (boceprevir alone); and regimen C, 40 mg of omeprazole once
daily for 5 consecutive days+800 mg of boceprevir three times daily
(8 h intervals) for 4 consecutive days+a single dose of 800 mg on day
5 (combination). Every treatment regimen was followed by a wash-out
period of 9 days. After observed intake of the medication with a standar-
dized breakfast at day 5 of every treatment period, blood samples for as-
sessment of pharmacokinetic parameters were collected during an 8 h
period.
Procedures
The study was approved by the Investigational Review Board of the
Radboud University Nijmegen Medical Centre, Nijmegen, The Nether-
lands. The study was conducted in accordance with Good Clinical Practice
and the Declaration of Helsinki. The study was registered at ClinicalTrials.
gov (NCT01470690). An advertisement for the study was published in
local newspapers and online. All participants signed informed consent
prior to screening evaluations and received monetary compensation
for their time. Subjects were admitted to the Clinical Research Centre
Nijmegen for the pharmacokinetic study days.
Study population
Healthy male and female subjects between the ages of 18 and 55 years
and with a body mass index (BMI) of 18–30 kg/m2 (extremes included)
were eligible for enrolment. Included participants had to be in a good,
age-appropriate health condition as established by physical examination,
medical history, electrocardiography and biochemical, haematological
and urine analyses within 4 weeks prior to day 1. Main exclusion criteria
were a history of sensitivity or idiosyncrasy to medicinal products or exci-
pients, a positive HIV, hepatitis B virus or HCV test result or the use of any
medication (for 2 weeks preceding dosing) except for acetaminophen.
Other exclusion criteria were participation in another drug trial or blood
donation within 60 days prior to day 1 of the study. Pregnant or breast-
feeding females were also not eligible.
Study drug and dosing
Omeprazole (Losecw, AstraZeneca, Zoetermeer, The Netherlands) was
administered as commonly used 40 mg enteric coated tablets. Omepra-
zole (with or without boceprevir) was taken between 08:00 h and
09:00 h with a breakfast. A treatment duration of five consecutive
days was chosen to reach a maximally elevated gastric pH.17 Subjects
were not allowed to eat or drink acidic foods or beverages.
The approved dose of boceprevir (Victrelisw, Merck Sharp & Dohme
Ltd, Hoddesdon, UK) is 800 mg every 8 h with food.16 In this study, sub-
jects took four capsules of 200 mg of boceprevir at approximately
08:00 h, 16:00 h and 0:00 h with a meal or snack.
On the pharmacokinetic sampling days the medication was taken at
the trial site and the subjects consumed a standardized breakfast within
5 min prior to the dose. The breakfast consisted of two slices of wheat
bread with butter [one slice with cheese and one with cervelat (cooked
smoked sausage)] and one glass of milk (in total 291 kcal, 21%
protein, 15% carbohydrate and 64% lipids).
Intake of medication at the clinical trial unit was supervised and
recorded by the study personnel. Drug intake at home was monitored
by the use of microelectronic monitoring system (MEMS) caps (Aardex
Ltd, Zug, Switzerland), which record the opening of the medication
bottle. The number of omeprazole tablets in the bottles and the weight
of the bottles containing the boceprevir capsules were recorded on
each visit day to assess adherence. Subjects were asked to write down
the exact times of medication intake in a booklet. Additionally, blood
samples were taken pre-dose on days 1 and 4 of every treatment
period to measure plasma concentrations of omeprazole and boceprevir
for determination of treatment adherence.
Pharmacokinetic sampling and safety assessments
Blood samples for assessment of pharmacokinetic parameters of boce-
previr and omeprazole were collected during an 8 h period at 0
(pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6 and 8 h after intake of the medi-
cation on day 5 of every treatment period. Blood samples for boceprevir
were collected into pre-chilled potassium-EDTA-containing tubes and
centrifuged for 15 min at 1500 g at 48C within 30 min after blood collec-
tion. Plasma (1.5 mL) was transferred to pre-chilled cryovials containing
75 mL of 85% phosphoric acid, mixed with a vortex mixer and stored at
≤208C within 1 h of sample collection.
Blood samples for omeprazole were collected into heparinized tubes
and centrifuged for 5 min at 1900 g at 208C. Plasma was transferred to
polypropylene tubes and stored at 2408C until further bioanalysis.
Blood samples for serum biochemistry and haematology were taken
on the day before every treatment period (day21) and on day 4 of every
treatment period. Screening for drugs of abuse in urine was carried out at
day 5 of every treatment period. A pregnancy test was done by perform-
ing a human chorionic gonadotropin blood test in all females at screen-
ing and on the day before starting treatment. Subjects were asked about
the presence of adverse events on each visit day.
Bioanalytical methods
Boceprevir (SCH 503034) is an approximately equal mixture of two dia-
stereomers: SCH 534128, the active diastereomer, and SCH 534129,
which is inactive. The predominant metabolic pathway produces inactive
stereoisomers, together called SCH 629144.18 Concentrations of bocepre-
vir were determined as the sum of concentrations of the two diastereo-
mers of boceprevir: SCH 534128 and SCH 534129. Concentrations of
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SCH 629144 were obtained as the sum of concentrations of four ana-
lytes, namely, SCH 783004, SCH 783005, SCH 783006 and SCH 783007.
The overall lower limit of quantification (LLOQ) was 0.0048 mg/L for
boceprevir and 0.0025 mg/L for SCH 629144. The calibration range for
SCH 534128, SCH 534129 and the four metabolites were from the
LLOQ to 5.20, 4.80 and 2.50 mg/L, respectively. Concentrations of both
diastereomers and their metabolites in collected plasma samples were
determined using HPLC–tandem mass spectrometry at PPD Global
Central Labs (Middleton, WI, USA).
Concentrations of omeprazole and its pharmacologically inactive
metabolites, 5-hydroxyomeprazole and omeprazole sulfone, in plasma
were analysed by use of a validated ultra-performance liquid chromatog-
raphy (UPLC) method with tunable UV detection. Sample preparation
consisted of liquid–liquid extraction by adding 50 mL of internal standard
[phenacetine (400 mg/mL)] and 2.5 mL of methyl tert-butyl ether/dichlor-
omethane (60:40; v/v) to 500 mL of plasma. The samples were shaken
for 5 min at 1500 rpm, followed by centrifugation at 1910 g for 5 min.
After freezing at 2408C for 5 min the organic supernatant was decanted
and evaporated at 378C under a stream of nitrogen gas. The residue was
reconstituted in 200 mL of acetonitrile/10 mM phosphate buffer, pH 7.05
(25:75; v/v), washed with 1.5 mL of hexane and mixed on a vortex mixer
for 5 min, followed by centrifugation at 1910 g for 5 min. Ten microlitres
of the reconstituted solution was injected into an Acquity UPLC System.
The mobile phases were (A) 10 mM phosphate buffer pH 7.05 and (B)
acetonitrile/10 mM phosphate buffer pH 7.05 (65:35; v/v). Chromato-
graphic separation was achieved on a BEH C18 column (1.7 mm,
100×2.1 mm) at a flow rate of 0.35 mL/min. Gradient run was pro-
grammed from 35% mobile phase B to 55% in 4.8 min. Omeprazole
and its metabolites were detected by the use of a UV detector at
302 nm. The lower limit of quantification and detection limit was
0.0100 mg/L for omeprazole, 0.0028 mg/L for 5-hydroxyomeprazole
and 0.0033 mg/L for omeprazole sulfone. The linear calibration ranges
in plasma were from 0.010 to 3.03 mg/L for omeprazole, from 0.0028
to 2.75 mg/L for 5-hydroxyomeprazole and from 0.0033 to 3.32 mg/L
for omeprazole sulfone. Validation results of the quality control
samples showed an accuracy in the linear calibration range varying
from 98.8% to 101.3% for omeprazole, from 97.5% to 106.3% for
5-hydroxyomeprazole and from 97.6% to 100.2% for omeprazole
sulfone. In this concentration range, the intra-day precision (coefficient
of variation) values varied from 1.9% to 4.3% for omeprazole, from
1.9% to 6.0% for 5-hydroxyomeprazole and from 1.7% to 4.7% for ome-
prazole sulfone. The inter-day precision (coefficient of variation) values
were 0–2.6%, 0–2.4% and 0–2.8%, respectively. The omeprazole
assay was performed at the laboratory of the Pharmacy Department of
the Radboud University Nijmegen Medical Centre (Nijmegen, The
Netherlands).
Pharmacokinetic analysis
Based on the individual plasma concentration–time data, the following
pharmacokinetic parameters of boceprevir (both diastereomers and
metabolites) were determined: the AUC from 0 to 8 h after intake
(AUC0–8), the maximum plasma concentration (Cmax), time of Cmax
(Tmax), the concentration at 8 h after intake (C8), the bioavailability-
adjusted volume of distribution (V/F), the apparent oral clearance (CL/F)
and the apparent elimination half-life (t1/2). t1/2 was only calculated if
there were two or more points (not including Cmax) in the elimination
phase of the plasma concentration–time curve with r2.0.80.
For omeprazole and metabolites the same parameters were deter-
mined. All pharmacokinetic parameters were calculated by non-
compartmental methods using the linear log trapezoidal rule.
Statistical analysis
The data obtained in this study were analysed according to an equiva-
lence approach that is recommended for pharmacokinetic interaction
studies.19,20 The main pharmacokinetic parameter to be evaluated in
this respect was the exposure to boceprevir, as expressed by AUC0–8.
The required sample size was calculated (power of 80%) assuming no
difference in AUC0–8 of boceprevir with or without omeprazole and an
intra-subject coefficient of variation of 22.5% of boceprevir AUCs. The
required number of participants was 20. Taking dropouts into account,
a total of 24 subjects were included in the study.
The geometric mean ratio estimates of all determined pharmacoki-
netic parameters of boceprevir (diastereomers and metabolites) with
omeprazole versus boceprevir alone and for omeprazole (and metabo-
lites) with versus without boceprevir, except for Tmax, were calculated
using mixed model analysis, with the Kenward–Roger approach for the
evaluation of fixed effects. In addition, the non-parametric Wilcoxon
signed rank test was used for Tmax values between the two different regi-
mens. Geometric mean ratio estimates with 90% CI entirely within the
range of 0.80–1.25 were considered to indicate no significant interaction.
Statistical analyses were carried out using SPSS software version 16.0
or higher (SPSS Inc., Chicago, IL, USA, 1989–2007) and SAS 9.2. Descrip-
tive pharmacokinetic statistics were calculated using WinNonlin version
5.3 (Pharsight Corporation, CA, USA).
Results
Baseline characteristics
Twenty-four healthy volunteers (15 males) were included in the
study. Subjects were all of Caucasian ethnicity and the median
(IQR) age and BMI were 31 (22–44) years and 23 (22–24) kg/m2,
respectively. The subjects were in good general health according
to medical history, physical examination, vital signs and laboratory
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Figure 1. Geometric mean plasma concentrations of boceprevir (SCH
534128+SCH 534129) and the active diastereomer (SCH 534128) after
multiple doses of 800 mg of boceprevir in the presence and absence of
steady-state omeprazole.
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data. All subjects completed the trial and were included in the
demographic, safety and pharmacokinetic analyses.
Adherence
The adherence to both boceprevir and omeprazole treatment
was good. Two subjects took omeprazole more than once per
day during the combination treatment and one subject missed
one dose of boceprevir during the boceprevir alone treatment.
All other subjects took all doses of boceprevir and omeprazole
according to pill count, diary, MEMS cap recordings and blood
concentrations. Twelve subjects (one to four times/subject)
took the dose of boceprevir (and/or omeprazole) outside a 2 h
time frame (07:00–09:00 h/15:00–17:00 h/23:00–01:00 h).
These deviations did not lead to exclusion of subjects from the
analysis.
Pharmacokinetics
Pharmacokinetic parameters were calculated on all available
data from the 24 subjects who were included in the trial.
The plasma concentration–time curves of boceprevir and the
active diastereomer SCH 534128 with and without omeprazole
are shown in Figure 1. The pharmacokinetic parameters of
boceprevir, both diastereomers and the metabolites together
as SCH 629144, after intake of boceprevir alone or in combin-
ation with omeprazole, are given in Table 1. For boceprevir
co-administered with omeprazole relative to boceprevir alone,
the geometric mean ratio estimates (90% CI) of boceprevir
AUC0–8 and Cmax were 0.92 (0.87–0.97) and 0.94 (0.86–1.02),
respectively. For the active diastereomer SCH 534128, the
geometric mean ratio estimates (90% CI) of AUC0–8 and Cmax
were 0.91 (0.87–0.97) and 0.94 (0.86–1.02) when boceprevir
was co-administered with omeprazole relative to boceprevir
alone.
Table 1. Comparison of pharmacokinetic parameters of steady-state boceprevir with and without co-administration of multiple doses
of omeprazole in healthy volunteers
Pharmacokinetic parameter
Boceprevir Boceprevir+omeprazole Boceprevir+omeprazole/boceprevir alone
n GM 95% CI n GM 95% CI na GM ratio estimate 90% CI
Boceprevir
Tmax (h)
b 24 2.5 (1.5–5.0) 24 3.0 (2.0–5.0) 24
Cmax (mg/L) 24 1.78 (1.56–2.02) 24 1.66 (1.47–1.89) 24 0.94 (0.86–1.02)
AUC0–8 (mg . h/L) 24 5.34 (4.75–6.00) 24 4.89 (4.37–5.48) 24 0.92 (0.87–0.97)
C8 (mg/L) 24 0.08 (0.07–0.10) 24 0.09 (0.07–0.12) 24 1.17 (0.97–1.42)
c
V/F (L) 23 235.0 (207.0–266.9) 19 249.7 (218.9–285.0) 19 1.07 (0.95–1.20)
CL/F (L/h) 24 149.8 (133.3–168.4) 24 163.6 (146.0–183.2) 24 1.09 (1.03–1.15)
t1/2 (h) 23 1.1 (1.0–1.2) 19 1.1 (1.0–1.2) 19 1.03 (0.95–1.12)
SCH 534128 (active)
Tmax (h)
b 24 2.5 (1.5–5.0) 24 3.5 (2.0–5.0) 24
Cmax (mg/L) 24 1.17 (1.03–1.32) 24 1.14 (1.01–1.29) 24 0.94 (0.86–1.02)
AUC0–8 (mg . h/L) 24 3.73 (3.33–4.19) 24 3.46 (3.09–3.87) 24 0.91 (0.87–0.97)
C8 (mg/L) 24 0.07 (0.05–0.08) 24 0.08 (0.06–0.10) 24 1.17 (0.97–1.42)
c
t1/2 (h) 23 1.1 (1.0–1.2) 19 1.1 (1.1–1.2) 19 1.02 (0.94–1.11)
SCH 534129 (inactive)
Tmax (h)
b 24 2 (1.5–5.0) 24 2.7 (1.0–5.0) 24
Cmax (mg/L) 24 0.63 (0.54–0.73) 24 0.55 (0.47–0.63) 24 0.86 (0.78–0.96)
c
AUC0–8 (mg . h/L) 24 1.59 (1.39–1.81) 24 1.42 (1.25–1.61) 24 0.89 (0.84–0.95)
C8 (mg/L) 24 0.01 (0.01–0.02) 24 0.02 (0.01–0.02) 24 1.21 (0.94–1.55)
c
t1/2 (h) 23 1 (0.9–1.1) 18 1.1 (1.0–1.2) 18 1.13 (1.00–1.28)
c
SCH 629144 (metabolites)
Tmax (h)
b 24 4 (2.5–5.0) 24 4 (3.0–6.0) 24
Cmax (mg/L) 24 4.85 (4.22–5.57) 24 5.37 (4.76–6.06) 24 1.11 (1.00–1.23)
AUC0–8 (mg . h/L) 24 22.10 (19.06–25.63) 24 22.35 (19.61–25.46) 24 1.01 (0.92–1.11)
C8 (mg/L) 24 1.35 (1.15–1.58) 24 1.70 (1.48–1.96) 24 1.27 (1.14–1.41)
c
t1/2 (h) 13 1.8 (1.7–1.9) 13 1.8 (1.6–2.1) 9 1.01 (0.89–1.14)
AUC0–8, area under the plasma concentration–time curve up to 8 h after intake; Cmax, maximum plasma concentration; Tmax, time to reach Cmax;
C8, concentration 8 h after intake; V/F, volume of distribution; CL/F, apparent oral clearance; t1/2, elimination half-life; GM, geometric mean.
aThe number of paired samples per parameter is given.
bFor Tmax, median+range is reported; the results of the Wilcoxon signed rank tests were P¼0.013 for boceprevir, P¼0.006 for SCH 534128, P¼0.056
for SCH 534129 and P¼0.149 for SCH 629144.
cGM ratio estimate for pharmacokinetic parameter is not bioequivalent with and without omeprazole.
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The plasma concentration–time curves of omeprazole
and the two metabolites 5-hydroxyomeprazole and omeprazole
sulfone after administration of omeprazole alone and with
boceprevir are shown in Figure 2(a and b), respectively. The
pharmacokinetic parameters of omeprazole and the metabo-
lites 5-hydroxyomeprazole and omeprazole sulfone, with and
without boceprevir, are shown in Table 2. For omeprazole co-
administered with boceprevir relative to omeprazole alone, the
geometric mean ratio estimates (90% CI) of AUC0–8 and Cmax
were 1.06 (0.90–1.25) and 1.03 (0.85–1.26), respectively.
The geometric mean ratio estimate with 90% CI of the main
pharmacokinetic parameter boceprevir AUC0–8 fell entirely
within the range of 0.80–1.25, which indicates no significant
interaction with omeprazole. The AUC0–8 of omeprazole also
lay within these limits and therefore no influence of boceprevir
on omeprazole exposure was found.
Bio-equivalence was also found or suggested for the other
pharmacokinetic parameters of boceprevir, both diastereomers
and their metabolites, as well as for all the parameters of ome-
prazole and its metabolite 5-hydroxyomeprazole. Only Tmax was
found to be statistical significantly later for boceprevir and the
active diastereomer SCH 534128 when omeprazole and bocepre-
vir were taken together compared with boceprevir alone. Inequi-
valence was also found in exposure to omeprazole sulfone.
Concentrations of this metabolite, formed by CYP3A4, were
lower in the presence of the CYP3A4 inhibitor boceprevir.
Adverse events and safety assessments
No serious adverse events were reported. In total 131 adverse
events were reported by 22 subjects after intake of study medi-
cation. Most frequently reported adverse experiences that were
possibly, probably or definitely drug related were dysgeusia
(n¼21 subjects), nausea (n¼7), abdominal pain (n¼6), head-
ache (n¼5), dry mouth (n¼4), fatigue (n¼4) and diarrhoea
(n¼4) (see Table S1, available as Supplementary data at JAC
Online). All adverse events were grade 1 or 2 in intensity. No add-
itional side effects were seen when omeprazole and boceprevir
were co-administered.
Discussion
This study demonstrates that the concomitant intake of omepra-
zole and boceprevir does not influence the pharmacokinetics
of either drug. Because omeprazole and other PPIs are widely
prescribed, available as over-the-counter drugs and frequently
used for long time periods, this is relevant information for clinical
practice.
Boceprevir is to be administered with food as this increases its
bioavailability substantially.16,21 Administration without food is
associated with a net loss of efficacy due to insufficient expos-
ure.21 In response to food ingestion, the stomach pH increases
and gastric emptying is delayed.22 For drugs with either
pH-dependent solubility or poor aqueous solubility, postprandial
changes in gastrointestinal pH and gastric emptying can influ-
ence the absorption of these drugs. Gastric pH is important for
the solubility and thus absorption of weakly acidic or basic
drugs. Boceprevir is a non-ionizable drug and its solubility is
therefore not expected to be pH dependent,23 which is confirmed
by the results of this study.
Boceprevir is poorly soluble in water23 and, in general, a
slowing of gastric emptying can increase the absorption of
poorly water-soluble drugs by increasing the time available for
dissolution.22 Although the Tmax of boceprevir was slightly, but
statistically significantly, delayed by adding omeprazole, this
did not result in a changed Cmax or AUC of boceprevir (Table 1).
Besides drug–drug interactions involving the absorption of
medications, interactions can also occur on drug metabolism.
Omeprazole is metabolized by CYP2C19 and CYP3A4 and
known to inhibit CYP2C19 and, possibly, to induce CYP1A2.1
Boceprevir is a potent inhibitor of CYP3A4/5 and is not metabo-
lized by CYP1A2 or CYP2C19. Therefore, no interaction on the
metabolism of boceprevir is expected. However, boceprevir
inhibits the CYP3A4 metabolism route of omeprazole, resulting
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Figure 2. Geometric mean plasma concentrations of omeprazole (a) and
5-hydroxyomeprazole and omeprazole sulfone (b) at steady-state of
40 mg of omeprazole with and without multiple doses of 800 mg of
boceprevir.
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in formation of a smaller amount of the metabolite omeprazole
sulfone. This led to somewhat higher concentrations of omepra-
zole itself and the 5-hydroxyomeprazole metabolite, although
the increases were not statistically significant.
PPIs are often (self-)prescribed for many acid-related diseases
as well as for the prevention of gastrointestinal bleeding. By spe-
cific inhibition of H+/K+-ATPase in gastric parietal cells, PPIs sup-
press gastric acid secretion and elevate intra-gastric pH. This
increased pH can lead to reduced solubility of concomitantly
administered drugs, resulting in lower plasma concentrations.
This has been shown for several classes of currently used medi-
cations, including some oral tyrosine kinase inhibitors used in on-
cology,2,3 various antifungal agents4–7 and a number of drugs
used in HIV treatment.10–15 For example, the AUC24 of atazana-
vir was 62% lower when 300/100 mg of atazanavir/ritonavir was
combined with 40 mg of omeprazole.14 Another example is
lower exposure to nelfinavir when 40 mg of omeprazole was
administered 30 min before intake of nelfinavir. This resulted in
a 36% lower AUC and a 39% lower Cmin of nelfinavir.
24 As a con-
sequence, reduced efficacy can be expected. In the case of lower
exposure to antimicrobial drugs, besides treatment failures, the
development of drug resistance is likely to occur. It would be
very unfortunate if this were to happen with boceprevir as
60%–70% of patients achieve a sustained virological response
with triple therapy containing boceprevir, a percentage substan-
tially higher than with dual therapy consisting of pegylated inter-
feron alfa and ribavirin.25,26
This study was conducted in healthy volunteers, which can
limit its interpretation in patients chronically infected with HCV.
The pharmacokinetics of boceprevir are not different in HCV-
positive or -negative patients, but in patients with hepatic impair-
ment higher plasma concentrations of boceprevir are found.16 It
is, however, not likely that higher concentrations of boceprevir
will affect the possibility of an interaction between boceprevir
and omeprazole. Another limitation could be that we used a
40 mg dose of omeprazole, which is the highest approved dose
for many indications.27 Since no interactions occurred with the
40 mg dose, lower doses of omeprazole will probably also not
affect the solubility and absorption of boceprevir. For a number
of indications, e.g. in peptic ulcer bleeding, higher doses of ome-
prazole are used.28 However, these higher doses of omeprazole
are generally not used for long periods of time and therefore
their influence, if any, on boceprevir absorption is not expected
to be substantial.
For most indications omeprazole is administered every 24 h,
but in this study omeprazole was sampled over only 8 h. We
Table 2. Comparison of pharmacokinetic parameters of steady-state omeprazole with and without co-administration of multiple doses of
boceprevir in healthy volunteers
Pharmacokinetic parameter
Omeprazole Omeprazole+boceprevir
Omeprazole+boceprevir/omeprazole
alone
n GM 95% CI n GM 95% CI na GM ratio estimate 90% CI
Omeprazole
Tmax (h)
b 24 3.5 (1.0–5.0) 24 4.0 (1.0–5.0) 24
Cmax (mg/L) 24 0.78 (0.61–0.98) 24 0.80 (0.64–1.01) 24 1.03 (0.85–1.26)
c
AUC0–8 (mg . h/L) 24 1.98 (1.51–2.61) 24 2.10 (1.56–2.83) 24 1.06 (0.90–1.25)
C8 (mg/L) 24 0.05 (0.03–0.08) 24 0.05 (0.03–0.10) 24 1.12 (0.75–1.67)
c
V/F (L) 18 27.24 (22.57–32.87) 17 28.65 (24.38–33.68) 13 1.03 (0.92–1.16)
CL/F (L/h) 24 20.18 (15.33–26.57) 24 19.02 (14.14–25.58) 24 0.95 (0.81–1.11)
t1/2 (h) 18 1.06 (0.89–1.26) 17 1.18 (0.92–1.53) 13 1.04 (0.91–1.19)
5-Hydroxyomeprazole
Tmax (h)
b 24 3.5 (1.0–5.0) 24 3.0 (1.0–5.0) 24
Cmax (mg/L) 24 0.23 (0.19–0.27) 24 0.26 (0.23–0.30) 24 1.13 (1.01–1.27)
c
AUC0–8 (mg . h/L) 24 0.70 (0.62–0.79) 24 0.82 (0.74–0.91) 24 1.16 (1.07–1.27)
c
C8 (mg/L) 23 0.03 (0.02–0.04) 24 0.04 (0.03–0.05) 23 1.25 (0.92–1.69)
c
t1/2 (h) 17 1.45 (1.23–1.71) 19 1.58 (1.29–1.94) 14 1.08 (0.97–1.19)
Omeprazole sulfone
Tmax (h)
b 24 4.0 (2.5–8.0) 24 5.0 (2.0–8.2) 24
Cmax (mg/L) 24 0.21 (0.16–0.27) 24 0.04 (0.03–0.06) 24 0.19 (0.15–0.25)
c
AUC0–8 (mg . h/L) 24 0.95 (0.69–1.31) 24 0.18 (0.11–0.28) 24 0.19 (0.14–0.26)
c
C8 (mg/L) 24 0.13 (0.09–0.18) 24 0.03 (0.02–0.04) 24 0.20 (0.16–0.25)
c
t1/2 (h) 13 4.03 (2.88–5.62) 7 3.19 (2.17–4.68) not feasible (n¼4)
AUC0–8, area under the plasma concentration–time curve up to 8 h after intake; Cmax, maximum plasma concentration; Tmax, time to reach Cmax; C8,
concentration 8 h after intake; V/F, volume of distribution; CL/F, apparent oral clearance; t1/2, elimination half-life; GM, geometric mean.
aThe number of paired samples per parameter is given.
bFor Tmax, median+range is reported; the results of the Wilcoxon signed rank tests were P¼0.716 for omeprazole, P¼0.600 for 5-hydroxyomeprazole
and P¼0.140 for omeprazole sulfone.
cGM ratio estimate for pharmacokinetic parameter is not bioequivalent with and without boceprevir.
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chose to do so since no large influence of boceprevir on omepra-
zole pharmacokinetics was expected and the dosing interval and
sampling time for boceprevir was 8 h.
In this study the PPI omeprazole was used. Although other
PPIs with boceprevir have not been studied, they have a similar
mechanism of action as they also strongly inhibit gastric acid
secretion in the parietal cells of the stomach. Because of the
physical and pharmaceutical properties of boceprevir and the
absence of significant drug–drug interaction with omeprazole,
it is very unlikely that other PPIs will reduce the solubility and
absorption of boceprevir.
To our knowledge, no drug–drug interaction studies with
boceprevir and histamine H2-antagonists or antacids have
been performed. No interaction is expected based on their
ability to increase intra-gastric pH, but interactions based on
other mechanisms, e.g. CYP3A4 inhibition by cimetidine, can
occur.
In conclusion, co-administration of multiple-dose omeprazole
did not have a clinically significant affect on boceprevir exposure.
Boceprevir did not meaningfully affect omeprazole exposure, but
did cause a 5-fold decrease in the formation of the omeprazole
sulfone (CYP3A4-mediated) metabolite. This reflects the known
CYP3A4 inhibitory property of boceprevir. This did not lead to a
clinically relevant increase in omeprazole or 5-hydroxyomeprazole
levels.
Due to the absence of clinically significant drug–drug inter-
action, boceprevir and omeprazole can be safely combined.
In the groups of healthy volunteers participating in this study,
co-administration of boceprevir and omeprazole was well
tolerated.
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